Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05304351 · ClinicalTrials.gov registry record · Phase 2

Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older

A Phase 2 study of Herpes Zoster and Shingles, sponsored by Curevo.

Active
Registry status
Phase 2
Development phase
1,516
Enrollment target
14
Study locations

NCT05304351 is a Phase 2 study of Herpes Zoster and Shingles that is active but no longer recruiting, run by Curevo. The registered enrollment target is 1,516 participants, below the 2,079-participant average among 16 other Herpes Zoster trials with a reported enrollment target (27% lower). The trial reports 14 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05304351, a Phase 2 study of Herpes Zoster and Shingles, is active but no longer recruiting, sponsored by Curevo.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
1,516 participants
Enrollment target
14
Study locations

Study Summary

The purpose of this study is to assess the safety and immunogenicity of amezosvatein (CRV-101), an investigational vaccine compared to Shingrix® for the prevention of herpes zoster in adults aged 50 years and older

Conditions Studied

Herpes Zoster Shingles

Interventions

  • BIOLOGICAL Shingrix
  • BIOLOGICAL Amezosvatein Antigen High Dose Arm A
  • BIOLOGICAL Amezosvatein Antigen Low Dose Arm B
  • BIOLOGICAL Amezosvatein Adjuvant Dose Arm D
  • BIOLOGICAL Amezosvatein Adjuvant Dose Arm F

Study Locations (14)

Texas

  • Curevo Investigational Site - Austin
  • Curevo Investigational Site - Dallas
  • Curevo Investigational Site - Euless

Florida

  • Curevo Investigational Site - Coral Gables
  • Curevo Investigational Site - Tampa

Kansas

  • Curevo Investigational Site - Lenexa
  • Curevo Investigational Site - Newton

Arizona

  • Curevo Investigational Site - Tempe

Illinois

  • Curevo Investigational Site - Oak Brook

Kentucky

  • Curevo Investigational Site - Lexington

Nevada

  • Curevo Investigational Site - Las Vegas

Oklahoma

  • Curevo Investigational Site - Edmond

Trial Details

FieldValue
Enrollment Target 1,516 participants
Start Date 2022-02-02
Est. Completion 2032-03-06
Phase Phase 2

Sponsor

Curevo

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05304351

The ClinicalTrials.gov registry entry for NCT05304351 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 1,516 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,079-participant average among 16 other Herpes Zoster trials with a reported enrollment target (27% lower). The listed sponsor is Curevo, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Herpes Zoster appearing as the primary indexed condition, and to 5 interventions - of which Shingrix is the first listed.

NCT05304351 reports 14 study locations spanning 10 distinct geographic areas - top geographies include Texas, Florida, Kansas.

Frequently Asked Questions

What is clinical trial NCT05304351 about?

NCT05304351 is a clinical study titled "Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older". The purpose of this study is to assess the safety and immunogenicity of amezosvatein (CRV-101), an investigational vaccine compared to Shingrix® for the prevention of herpes zoster in adults aged 50 years and older

What is the current status of trial NCT05304351?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 1,516 participants. The study started on 2022-02-02. Estimated completion is 2032-03-06.

What conditions does trial NCT05304351 study?

This clinical trial studies the following conditions: Herpes Zoster, Shingles.

What interventions are being tested in trial NCT05304351?

The interventions under investigation include: Shingrix (BIOLOGICAL), Amezosvatein Antigen High Dose Arm A (BIOLOGICAL), Amezosvatein Antigen Low Dose Arm B (BIOLOGICAL), Amezosvatein Adjuvant Dose Arm D (BIOLOGICAL), Amezosvatein Adjuvant Dose Arm F (BIOLOGICAL).

Who is sponsoring clinical trial NCT05304351?

This trial is sponsored by Curevo, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05304351 being conducted?

This trial has 14 study locations across Arizona, Florida, Illinois, Kansas, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Herpes Zoster

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Herpes Zoster

All registered trials for this condition

Shingles

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.